164BV, Associate Director / Senior Scientist, Cancer Immunotherapy

Associate Director / Senior Scientist, Cancer Immunotherapy
Job Code 164BV

Description
Fate’s Cancer Immunotherapy group is seeking a talented and highly motivated scientist with expertise in oncology and stroma immunobiology to join a multidisciplinary team dedicated to the discovery of novel cellular therapeutics for the treatment of cancer. The successful candidate will play a leading role in the research and translation of new biologic modalities for off-the-shelf cancer immunotherapy. Specifically, the candidate will be tasked to drive ongoing efforts to identify novel strategies to improve effector persistence across tumor microenvironment and histocompatibility barrier. The candidate must have in depth knowledge of NK cell and T cell immunology, cancer biology, effector cell dysfunction and exhaustion, immunosuppression, metabolism and trafficking. The position will require independent research as well as coordination with the greater cancer immunotherapy and cellular engineering groups. This is a full-time position reporting to the Vice President of Cancer Immunotherapy and is located at our corporate headquarters in San Diego, CA.

Download a PDF of the job description for more details:
pdf version164BV, Associate Director / Senior Scientist, Cancer Immunotherapy

For consideration send cover letter and curriculum vitae to: careers@fatetherapeutics.com and reference job 164BV.

About Fate Therapeutics, Inc.
Fate Therapeutics is a biopharmaceutical company dedicated to the development of programmed cellular immunotherapeutics for the treatment of cancer and immune disorders. The Company’s cell-based product pipeline is comprised of off-the-shelf immuno-oncology therapeutics, including NK- and T-cell-based candidates derived from induced pluripotent cells, and immuno-regulatory therapeutics, including hematopoietic cell-based candidates for protecting the immune system of patients undergoing hematopoietic cell transplantation and for suppressing auto-reactive T cells of patients with auto-immune disorders. Its adoptive cell therapy candidates are based on the Company’s novel ex vivo cell programming approach, which it applies to modulate the therapeutic function and direct the fate of immune cells. Fate Therapeutics is headquartered in San Diego, CA. For more information, please visit www.fatetherapeutics.com.